spironolactone has been researched along with Heart Disease, Ischemic in 20 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "If spironolactone has beneficial effects on HRV, this would contribute to favorable results." | 5.31 | Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. ( Korkmaz, ME; Müderrisoğlu, H; Ozin, B; Uluçam, M, 2000) |
| "Additionally, ischemic heart disease adversely impacts the clinical course of HFrEF patients; however, its role in HFpEF is not fully understood." | 3.01 | Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). ( Elsaid, O; McCullough, PA; Rahimi, G; Tecson, KM, 2021) |
| "Aldosterone blockade has been shown to reduce the incidence of sudden death in patients with heart failure." | 2.73 | Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. ( Donnan, PT; Pringle, SD; Shah, NC; Struthers, AD, 2007) |
| "Ischemic heart failure is induced by myocardial ischemia, which is probably the commonest cause of left ventricular systolic dysfunction." | 2.42 | [Ischemic heart failure]. ( Hori, M; Inoue, K, 2003) |
| "In conclusion, hypokalemia is extremely common in patients presenting with VT/VF, much more so than in patients with CHF alone." | 1.56 | Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study). ( Basil, A; Cooper, JM; Gangireddy, C; Greenberg, RM; Laslett, DB; Whitman, IR; Yesenosky, GA, 2020) |
| "We evaluated the effects of RU28318 (RU), a selective mineralocorticoid receptor (MR) antagonist, Captopril (Capt), an angiotensin converting enzyme inhibitor, and Losartan (Los), an angiotensin receptor blocker, alone or in combination with ischemia/reperfusion- (I/R-) induced cardiac dysfunction in hearts obtained from normal and diabetic rats." | 1.39 | RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes. ( Akhtar, S; Al-Rashdan, I; Babiker, F; Benter, IF; Yousif, M, 2013) |
| "Eplerenone-treated HF rats had lower plasma TNF-alpha, interleukin (IL)-1beta and IL-6, less COX-2 staining of small blood vessels penetrating PVN, fewer PVN neurons expressing Fra-like activity (indicating chronic neuronal activation), and fewer PVN neurons staining for TNF-alpha, IL-1beta, and CRH than vehicle-treated HF rats." | 1.33 | Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. ( Beltz, T; Felder, RB; Johnson, AK; Johnson, RF; Kang, YM; Weiss, RM; Yu, Y; Zhang, ZH, 2006) |
| "If spironolactone has beneficial effects on HRV, this would contribute to favorable results." | 1.31 | Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. ( Korkmaz, ME; Müderrisoğlu, H; Ozin, B; Uluçam, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (75.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laslett, DB | 1 |
| Cooper, JM | 1 |
| Greenberg, RM | 1 |
| Yesenosky, GA | 1 |
| Basil, A | 1 |
| Gangireddy, C | 1 |
| Whitman, IR | 1 |
| Rahimi, G | 1 |
| Tecson, KM | 1 |
| Elsaid, O | 1 |
| McCullough, PA | 1 |
| Benter, IF | 1 |
| Babiker, F | 1 |
| Al-Rashdan, I | 1 |
| Yousif, M | 1 |
| Akhtar, S | 1 |
| Li, MJ | 1 |
| Huang, CX | 1 |
| Okello, E | 1 |
| Yanhong, T | 1 |
| Mohamed, S | 1 |
| de Peuter, OR | 1 |
| Lip, GY | 1 |
| Souverein, PC | 1 |
| Klungel, OH | 1 |
| de Boer, A | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Edfors, K | 1 |
| Andersen, SE | 1 |
| Inoue, K | 1 |
| Hori, M | 1 |
| Rutten, FH | 1 |
| Grobbee, DE | 1 |
| Hoes, AW | 1 |
| Rochetaing, A | 1 |
| Chapon, C | 1 |
| Marescaux, L | 1 |
| Le Bouil, A | 1 |
| Furber, A | 1 |
| Kreher, P | 1 |
| Weber, KT | 1 |
| Jaffe, IZ | 1 |
| Mendelsohn, ME | 1 |
| Nehme, JA | 1 |
| Lacolley, P | 1 |
| Labat, C | 1 |
| Challande, P | 1 |
| Robidel, E | 1 |
| Perret, C | 1 |
| Leenhardt, A | 1 |
| Safar, ME | 1 |
| Delcayre, C | 1 |
| Milliez, P | 1 |
| McAlister, FA | 1 |
| Tu, JV | 1 |
| Newman, A | 1 |
| Lee, DS | 1 |
| Kimber, S | 1 |
| Cujec, B | 1 |
| Armstrong, PW | 1 |
| Chai, W | 1 |
| Garrelds, IM | 1 |
| de Vries, R | 1 |
| Danser, AH | 1 |
| Kang, YM | 1 |
| Zhang, ZH | 2 |
| Johnson, RF | 1 |
| Yu, Y | 1 |
| Beltz, T | 1 |
| Johnson, AK | 1 |
| Weiss, RM | 2 |
| Felder, RB | 2 |
| Jotkowitz, AB | 1 |
| Porath, A | 1 |
| Shotan, A | 1 |
| Mittelman, M | 1 |
| Grossman, E | 1 |
| Zimlichman, R | 1 |
| Lewis, BS | 1 |
| Caspi, A | 1 |
| Gottlieb, S | 1 |
| Garty, M | 1 |
| Shah, NC | 1 |
| Pringle, SD | 1 |
| Donnan, PT | 1 |
| Struthers, AD | 1 |
| Korkmaz, ME | 1 |
| Müderrisoğlu, H | 1 |
| Uluçam, M | 1 |
| Ozin, B | 1 |
| Cleland, JG | 1 |
| John, J | 1 |
| Dhawan, J | 1 |
| Clark, A | 1 |
| Francis, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for spironolactone and Heart Disease, Ischemic
| Article | Year |
|---|---|
[Ischemic heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Fib | 2003 |
What is the optimal medical management of ischaemic heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2001 |
3 trials available for spironolactone and Heart Disease, Ischemic
| Article | Year |
|---|---|
Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Creatinine; Diabetes Mellitus; Disease Progress | 2021 |
Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology.
Topics: Administration, Oral; Adult; Aged; Diastole; Diuretics; Dose-Response Relationship, Drug; Double-Bli | 2009 |
Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.
Topics: Aged; Aldosterone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cross-Over Studies; Double-Blind Me | 2007 |
15 other studies available for spironolactone and Heart Disease, Ischemic
| Article | Year |
|---|---|
Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study).
Topics: Aged; Cardiomyopathies; Case-Control Studies; Diarrhea; Diuretics; Female; Heart Failure; Humans; Hy | 2020 |
RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diab | 2013 |
Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin-Converting Enzyme | 2011 |
Assessment of drug treatment quality in two Danish health-care centres.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2011 |
Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2003 |
Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.
Topics: Action Potentials; Animals; Cardiotonic Agents; Coronary Circulation; Drug Therapy, Combination; Ele | 2003 |
The neuroendocrine-immune interface gone awry in aldosteronism.
Topics: Aldosterone; Animals; Central Nervous System; Heart Failure; Humans; Hyperaldosteronism; Kidney; Min | 2004 |
Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Adenoviridae; Aldosterone; Angiotensin II; Angiotensin | 2005 |
Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure.
Topics: Animals; Carotid Arteries; Compliance; Drug Therapy, Combination; Echocardiography; Elasticity; Fibr | 2005 |
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting | 2006 |
Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
Topics: Aldosterone; Animals; Cardiotonic Agents; Drug Interactions; Eplerenone; Heart; Hemodynamics; In Vit | 2006 |
Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure.
Topics: Animals; Cytokines; Drug Synergism; Echocardiography; Eplerenone; Etanercept; Heart Failure; Hypotha | 2006 |
Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Calc | 2006 |
Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Circadian Rhythm; Diuretics; Echocardiography; Electrocardiography, | 2000 |
The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure.
Topics: Action Potentials; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Capto | 2002 |